PrEP

Implementing PrEP in retail community pharmacies increases patient accessibility but may be difficult to incorporate without modifying workflow.

Removing the word ‘risk’ from discussions of HIV PrEP and focusing more on environment and empowerment concerns are beneficial in this patient population.

Cabotegravir showed promising results in preventing HIV transmission in men, women, and transgender women with similar rates of adverse events to oral PrEP options.

The partnership to deliver HIV medications will reduce transportation and access barriers for patients, especially in underserved communities.

Many laws also allow physicians to decide which information they disclose to guardians or fail to address inadvertent breaches of confidentiality through insurance billing and claims.

The latest data indicate that the formulation can provide up to 6 months of full protection against multiple virus challenges.

Participants also generally prefer newer injectable pre-exposure prophylaxis compared to pills for HIV prevention.

Apretude is an antiretroviral drug that inhibits HIV replication by binding to the active site of integrase and blocking the strand transfer step of retroviral DNA integration.

Pharmacists play an important role in providing education and support with adherence to PrEP in populations with a high risk for HIV infection.

Data from a recent survey reflect a resounding shift toward the role of pharmacies becoming sites for primary care.

NRTIs TAF and TDF are increasingly being used as preexposure prophylaxis (PrEP) to prevent HIV around the world.

Study findings provide insight into factors preventing the uptake of pre-exposure prophylaxis for HIV among Black female adolescents and emerging adults and provide potential strategies to improve uptake.

Although progress has been made in pre-exposure prophylaxis use, there are still significant barriers for many patients.

Following the approval of cabotegravir in 2021, governments and donor agencies in low- and middle-income countries are contemplating replacing oral pre-exposure prophylaxis or augmenting the approach with long-acting treatment.

Study finds urgent need for aggressive expansion of pre-exposure prophylaxis among people who inject drugs to reduce the spread of HIV.

Due to the correlation between virologic suppression and antiretroviral therapy adherence, understanding the impediments of adherence is of the utmost importance.

Challenges for uptake of long-acting injectable pre-exposure prophylaxis in populations at risk for HIV include fear of needles, potential adverse effects, and concerns about diminished efficacy.

PrEP reduces the risk of getting HIV from sex by about 99% for certain patient population with consistent adherence.

Although the number of new HIV infections in the world have declined, there are still regions that are geographically heterogenous that have reported an increase in infection rates.

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, discusses how the new once every 2-month injectable PrEP has shown potential to increase adherence among populations with the greatest need.

Although clinicians cited lack of time as a reason for not using patient-reported outcomes, patients with HIV viewed their use very positively.

However, lack of access and awareness about pre-exposure prophylaxis, medication cost, and underestimating disease risk are all barriers to PrEP.

Investigators examined the impact of daily oral tenofovir disoproxil fumarate in combination with emtricitabine to see the effect on the microbiota in South African women.

Clinical studies have shown similar efficacy between emtricitabine and tenofovir alafenamide (Descovy) and emtricitabine and tenofovir disoproxil fumarate (Truvada) for individuals at risk for HIV infection.

There is not yet an FDA-approved treatment available for monkeypox, but existing antiviral agents have been found to be effective in vitro and in animal studies.